[an error occurred while processing this directive] | [an error occurred while processing this directive]
Research progress on influencing factors of radiation-induced oral mucositis
Yin Yan1,2, Zhang Jingping1
1Xiangya Nursing College of Central South University, Changsha 410013, China; 2Department of Radiation Oncology, The First Affiliated Hospital of University of South China, Hengyang 421001, China
Abstract Radiation-induced oral mucositis (RIOM) is a common toxicity in patients receiving radiotherapy for head and neck cancer. RIOM not only significantly affects the oral function of patients, but also affects the short-term and long-term quality of life. In severe cases, it can reduce the tumor control rate and thus impact the survival of patients. The influencing factors of RIOM has been intensively studied, whereas the conclusions of some studies are inconsistent. In this article, the research progresses on the influencing factors of RIOM in recent years were summarized, aiming to provide the basis for the prevention and management of RIOM.
Yin Yan,Zhang Jingping. Research progress on influencing factors of radiation-induced oral mucositis[J]. Chinese Journal of Radiation Oncology, 2020, 29(9): 799-803.
Yin Yan,Zhang Jingping. Research progress on influencing factors of radiation-induced oral mucositis[J]. Chinese Journal of Radiation Oncology, 2020, 29(9): 799-803.
[1] Maria OM, Eliopoulos N, Muanza T. Radiation-induced oral mucositis[J]. Front Oncol, 2017, 7(1):89. DOI:10.3389/fonc.2017.00089. [2] Nishii M, Soutome S, Kawakita A, et al. Factors associated with severe oral mucositis and candidiasis in patients undergoing radiotherapy for oral and oropharyngeal carcinomas:a retrospective multicenter study of 326 patients[J]. Support Care Cancer, 2019, 28(3):1069-1075. DOI:10.1007/s00520-019-04885-z. [3] Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy:a systematic literature review[J]. Radiother Oncol, 2003, 66(3):253-262. DOI:10.1016/S0167-8140(02)00404-8. [4] Lundberg M, Saarilahti K, Makitie AA, et al. TGFbeta1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis[J]. Oral Oncol, 2010, 46(5):369-372. DOI:10.1016/j.oraloncology.2010.02.012. [5] Vera-Llonch M, Oster G, Hagiwara M, et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma[J]. Cancer, 2006, 106(2):329-336. DOI:10.1002/cncr.21622. [6] Chen S, Lai Y, Liao C, et al. Changes of symptoms and depression in oral cavity cancer patients receiving radiation therapy[J]. Oral Oncol, 2010, 46(7):509-513. DOI:10.1016/j.oraloncology.2010.02.024. [7] Berger K, Schopohl D, Bollig A, et al. Burden of oral mucositis:a systematic review and implications for future research[J]. Oncol Res Treat, 2018, 41(6):399-405. DOI:10.1159/000487085. [8] Chen S, Lai Y, Huang B, et al. Changes and predictors of radiation-induced oral mucositis in patients with oral cavity cancer during active treatment[J]. Eur J Oncol Nur, 2015, 19(3):214-219. DOI:10.1016/j.ejon.2014.12.001. [9] Hua X, Chen L, Zhu Q, et al. Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy:a prospective clinical trial[J]. Support Care Cancer, 2019, 27(10):3759-3767. DOI:10.1007/s00520-019-4643-5. [10] Lalla RV, Treister N, Sollecito T, et al. Oral complications at 6 months after radiation therapy for head and neck cancer[J]. Oral Dis, 2017, 23(8):1134-1143. DOI:10.1111/odi.12710. [11] Riley P, Glenny AM, Worthington HV, et al. Interventions for preventing oral mucositis in patients with cancer receiving treatment:oral cryotherapy[J]. Cochrane Database Syst Rev, 2015(12): D11552. DOI:10.1002/14651858. CD011552.pub2. [12] Zhu X, Yang X, Chao Y, et al. The potential effect of oral microbiota in the prediction of mucositis during radiotherapy for nasopharyngeal carcinoma[J]. EBioMedicine, 2017, 18(1):23-31. DOI:10.1016/j.ebiom.2017.02.002. [13] 中华医学会放射肿瘤治疗学分会. 放射性口腔黏膜炎防治策略专家共识(2019)[J]. 中华放射肿瘤学杂志, 2019,28(9):641-647. DOI:10.3760/cma.j.issn.1004-4221.2019.09.001.Radiation Oncology Society of Chinese Medical Association. Expert consensus on prevention and treatment strategies of radiation-induced oral mucositis (2019)[J]. Chin J Radiat Oncol, 2019,28(9):641-647. DOI:10.3760/cma.j.issn.1004-4221.2019.09.001. [14] Eilers J, Million R. Clinical update:prevention and management of oral mucositis in patients with cancer[J]. Semin Oncol Nur, 2011, 27(4):e1-e16. DOI:10.1016/j.soncn.2011.08.001. [15] Pereira IF, Firmino RT, Meira HC, et al. Radiation-induced oral mucositis in brazilian patients:prevalence and associated factors[J]. in vivo, 2019, 33(2):605-609. DOI:10.21873/invivo.11517. [16] Pignon T, Horiot JC, Van den Bogaert W, et al. No age limit for radical radiotherapy in head and neck tumours[J]. Eur J Cancer, 1996, 32A (12):2075-2081. DOI:10.1016/s0959-8049(96)00265-1. [17] Sroussi HY, Epstein JB, Bensadoun RJ, et al. Common oral complications of head and neck cancer radiation therapy:mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis[J]. Cancer Med, 2017, 6(12):2918-2931. DOI:10.1002/cam4.1221. [18] Saito N, Imai Y, Muto T, et al. Low body mass index as a risk factor of moderate to severe oral mucositis in oral cancer patients with radiotherapy[J]. Support Care Cancer, 2012, 20(12):3373-3377. DOI:10.1007/s00520-012-1620-7. [19] Orlandi E, Iacovelli NA, Rancati T, et al. Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients[J]. Oral Oncol, 2018, 86(4):266-272. DOI:10.1016/j.oraloncology.2018.10.006. [20] Li K, Yang L, Xin P, et al. Impact of dose volume parameters and clinical factors on acute radiation oral mucositis for locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemoradiotherapy[J]. Oral Oncol, 2017, 72(1):32-37. DOI:10.1016/j.oraloncology.2017.06.026. [21] Vera-Llonch M, Oster G, Hagiwara M, et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma[J]. Cancer, 2006, 106(2):329-336. DOI:10.1002/cncr.21622. [22] 李小冬, 郑晓宇. 鼻咽癌调强放疗患者放射性口腔黏膜炎发生的主要相关因素分析[J]. 南京医科大学学报(社会科学版), 2011,11(2):134-137. Li XD, Zheng XY. Analysis of the main related factors of radiation oral mucositis in patients with nasopharyngeal carcinoma treated with intensity modulated radiotherapy[J]. J Nanjing Med Univ (Soc Sci), 2011, 11(2):134-137. [23] 王鲁, 曹咏梅, 史金晔. 鼻咽癌调强放疗后放射性口腔黏膜炎发生的危险因素分析[J]. 中国中西医结合耳鼻咽喉科杂志, 2017, 25(6):456-459. Wang L, Cao YM, Shi JY. Risk factors of radiation-induced oral mucositis after intensity modulated radiotherapy for nasopharyngeal carcinoma[J]. Chin J Otorhinolaryngol Inte Tradit West Med, 2017, 25(6):456-459. [24] Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy[J]. Cancer, 2008, 113(10):2704-2713. DOI:10.1002/cncr.23898. [25] 朱晓霞, 陈龙华, 晁漪澜. 鼻咽癌患者放射性口腔炎的危险因素分析[J]. 实用医学杂志, 2014, 30(16):2583-2585. Zhu XX, Chen LH, Chao YL. Risk factors of radiation stomatitis in patients with nasopharyngeal carcinoma[J]. Pract Med J, 2014, 30(16):2583-2585. [26] Ren J, Dai X, Yan G, et al. Acute oral mucositis in nasopharyngeal carcinoma patients treated with radiotherapy:association with genetic polymorphism in DNA DSB repair genes[J]. Int J Radiat Biol, 2013, 90(3):256-261. DOI:10.3109/09553002.2014.873558. [27] Brzozowska A, Homa-mlak I, mlak R, et al. Polymorphism of regulatory region of GHRLgene (-2531C>T) as a promising predictive factor for radiotherapy-induced oral mucositis in patients with head neck cancer[J]. Head Neck, 2018, 40(8):1799-1811. DOI:10.1002/hed.25154. [28] Mlak R, Powrozek T, Brzozowska A, et al. RRM1 gene expression evaluated in the liquid biopsy (blood cfRNA) as a non-invasive, predictive factor for radiotherapy-induced oral mucositis and potential prognostic biomarker in head and neck cancer patients[J]. Cancer Biomark, 2018, 22(4):657-667. DOI:10.3233/CBM-171082. [29] Hou J, Zheng H, Li P, et al. Distinct shifts in the oral microbiota are associated with the progression and aggravation of mucositis during radiotherapy[J]. Radiother Oncol, 2018, 129(1):44-51. DOI:10.1016/j.radonc.2018.04.023. [30] Bossi P, Bergamini C, Miceli R, et al. Salivary cytokine levels and oral mucositis in head and neck cancer patients treated with chemotherapy and radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2016, 96(5):959-966. DOI:10.1016/j.ijrobp.2016.08.047. [31] Normando AGC, Rocha CL, de Toledo IP, et al. Biomarkers in the assessment of oral mucositis in head and neck cancer patients:a systematic review and meta-analysis[J]. Support Care Cancer, 2017, 25(9):2969-2988. DOI:10.1007/s00520-017-3783-8. [32] Brzozowska A, mlak R, Golebiowski P, et al. Status of hydration assessed by bioelectrical impedance analysis:a valuable predictive factor for radiation-induced oral mucositis in head and neck cancer patients[J]. Clin Transl Oncol, 2019, 21(5):615-620. DOI:10.1007/s12094-018-1963-8. [33] Jirkovska M, Novak T, Malinova B, et al. Three-dimensional conformal radiotherapy versus intensity modulated radiotherapy with simultaneous integrated boost in the treatment of locally advanced head and neck carcinoma[J]. Neoplasma, 2019, 66(5):830-838. DOI:10.4149/neo_2018_181209N941. [34] Lewis GD, Holliday EB, Kocak-Uzel E, et al. Intensity-modulated proton therapy for nasopharyngeal carcinoma:Decreased radiation dose to normal structures and encouraging clinical outcomes[J]. Head Neck, 2016, 38(Suppl 1):E1886-E1895. DOI:10.1002/hed.24341. [35] Holliday EB, Frank SJ. Proton therapy for nasopharyngeal carcinoma[J]. Chin Clin Oncol, 2016, 5(2):25. DOI:10.21037/cco.2016.03.05. [36] Vogel J, Both S, Kirk M, et al. Proton therapy for pediatric head and neck malignancies[J]. Pediat Blood Cancer, 2018, 65(2):e26858. DOI:10.1002/pbc.26858. [37] Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy:a systematic literature review[J]. Radiother Oncol, 2003, 66(3):253-262. DOI:10.1016/S0167-8140(02)00404-8. [38] Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers:results of the EORTC 22851 randomized trial[J]. Radiother Oncol, 1997, 44(2):111-121. DOI:10.1016/s0167-8140(97)00079-0 [39] Machtay M, Moughan J, Farach A, et al. Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer:an RTOG analysis[J]. Int J Radiat Oncol Biol Phys, 2012, 84(4):983-989. DOI:10.1016/j.ijrobp.2012.03.005. [40] Li K, Yang L, Xin P, et al. Impact of dose volume parameters and clinical factors on acute radiation oral mucositis for locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemoradiotherapy[J]. Oral Oncol, 2017, 72(1):32-37. DOI:10.1016/j.oraloncology.2017.06.026. [41] 叶峰. 鼻咽癌调强放疗放射毒性与临床及放射剂量学因素的相关性分析[D]. 广州:南方医科大学, 2012. Ye F. Correlation analysis of clinical and dosimetric factors with radiation toxicity of intensity modulated radiotherapy for nasopharyngeal carcinoma[D]. Guangzhou:Southern Medical University, 2012. [42] Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer:a meta-analysis[J]. Lancet, 2006, 368(9538):843-854. DOI:10.1016/S0140-6736(06)69121-6. [43] Xu T, Hu C, Zhu G, et al. Preliminary results of a phase Ⅲ randomized study comparing chemotherapy neoadjuvantly or concurrently with radiotherapy for locoregionally advanced nasopharyngeal carcinoma[J]. Med Oncol, 2012, 29(1):272-278. DOI:10.1007/s12032-010-9803-x. [44] Chen L, Hu C, Chen X, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma:a phase 3 multicentre randomised controlled trial[J]. Lancet Oncol, 2012, 13(2):163-171. DOI:10.1016/S1470-2045(11)70320-5. [45] Xu T, Liu Y, Dou S, et al. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma:Results of a randomized phase Ⅱ study[J]. Oral Oncol, 2015, 51(9):875-879. DOI:10.1016/j.oraloncology.2015.06.008.
2020, Vol. 29 
